Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.29
AZN's Cash-to-Debt is ranked lower than
79% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. AZN: 0.29 )
Ranked among companies with meaningful Cash-to-Debt only.
AZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 0.88 Max: 10.55
Current: 0.29
0.19
10.55
Equity-to-Asset 0.21
AZN's Equity-to-Asset is ranked lower than
93% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. AZN: 0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
AZN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.43 Max: 0.59
Current: 0.21
0.21
0.59
Debt-to-Equity 1.30
AZN's Debt-to-Equity is ranked lower than
90% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. AZN: 1.30 )
Ranked among companies with meaningful Debt-to-Equity only.
AZN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.44 Max: 1.45
Current: 1.3
0.03
1.45
Debt-to-EBITDA 2.31
AZN's Debt-to-EBITDA is ranked lower than
65% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. AZN: 2.31 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AZN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09  Med: 1.11 Max: 2.55
Current: 2.31
0.09
2.55
Interest Coverage 6.55
AZN's Interest Coverage is ranked lower than
78% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. AZN: 6.55 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 4.19  Med: 8.2 Max: 19.13
Current: 6.55
4.19
19.13
Piotroski F-Score: 6
Altman Z-Score: 1.75
Beneish M-Score: -2.61
WACC vs ROIC
6.43%
16.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 24.93
AZN's Operating Margin % is ranked higher than
88% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. AZN: 24.93 )
Ranked among companies with meaningful Operating Margin % only.
AZN' s Operating Margin % Range Over the Past 10 Years
Min: 8.05  Med: 28.16 Max: 38.09
Current: 24.93
8.05
38.09
Net Margin % 16.01
AZN's Net Margin % is ranked higher than
83% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. AZN: 16.01 )
Ranked among companies with meaningful Net Margin % only.
AZN' s Net Margin % Range Over the Past 10 Years
Min: 4.64  Med: 19.12 Max: 29.72
Current: 16.01
4.64
29.72
ROE % 26.23
AZN's ROE % is ranked higher than
92% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. AZN: 26.23 )
Ranked among companies with meaningful ROE % only.
AZN' s ROE % Range Over the Past 10 Years
Min: 5.9  Med: 31.4 Max: 45.52
Current: 26.23
5.9
45.52
ROA % 5.67
AZN's ROA % is ranked higher than
63% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. AZN: 5.67 )
Ranked among companies with meaningful ROA % only.
AZN' s ROA % Range Over the Past 10 Years
Min: 2.2  Med: 12.84 Max: 18.34
Current: 5.67
2.2
18.34
ROC (Joel Greenblatt) % 70.29
AZN's ROC (Joel Greenblatt) % is ranked higher than
93% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. AZN: 70.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30.37  Med: 119.25 Max: 199.64
Current: 70.29
30.37
199.64
3-Year Revenue Growth Rate 5.10
AZN's 3-Year Revenue Growth Rate is ranked lower than
51% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. AZN: 5.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AZN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.9  Med: 2.5 Max: 19.9
Current: 5.1
-9.9
19.9
3-Year EBITDA Growth Rate 0.90
AZN's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. AZN: 0.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AZN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 10.1 Max: 24.8
Current: 0.9
-30.1
24.8
3-Year EPS without NRI Growth Rate 21.10
AZN's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. AZN: 21.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AZN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: 11.7 Max: 70
Current: 21.1
-48.9
70
GuruFocus has detected 7 Warning Signs with AstraZeneca PLC AZN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AZN's 30-Y Financials

Financials (Next Earnings Date: 2018-02-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

AZN Guru Trades in Q4 2016

Sarah Ketterer 514,612 sh (New)
Steven Cohen 676,000 sh (New)
Pioneer Investments 1,194,403 sh (+167.36%)
PRIMECAP Management 25,980,275 sh (+50.06%)
Dodge & Cox 49,613,588 sh (+17.60%)
NWQ Managers 945,170 sh (+12.55%)
Murray Stahl 28,302 sh (unchged)
Francis Chou 13,000 sh (unchged)
John Hussman 2,000 sh (unchged)
Manning & Napier Advisors, Inc 495,960 sh (unchged)
Ken Fisher 1,950,999 sh (-1.34%)
Andreas Halvorsen 2,859,129 sh (-31.53%)
Jeremy Grantham 240,631 sh (-59.54%)
Jim Simons 1,394,800 sh (-75.54%)
David Dreman 180 sh (-86.37%)
» More
Q1 2017

AZN Guru Trades in Q1 2017

Charles Brandes 236,779 sh (New)
Sarah Ketterer 735,062 sh (+42.84%)
PRIMECAP Management 34,310,950 sh (+32.07%)
Dodge & Cox 56,906,499 sh (+14.70%)
Murray Stahl 28,302 sh (unchged)
John Hussman 2,000 sh (unchged)
Steven Cohen 1,200,000 sh (unchged)
David Dreman Sold Out
Francis Chou Sold Out
Andreas Halvorsen Sold Out
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Manning & Napier Advisors, Inc Sold Out
Pioneer Investments 1,185,803 sh (-0.72%)
Ken Fisher 1,921,092 sh (-1.53%)
NWQ Managers 710,935 sh (-24.78%)
» More
Q2 2017

AZN Guru Trades in Q2 2017

Jim Simons 130,700 sh (New)
Steven Cohen 603,108 sh (New)
David Dreman 180 sh (New)
Ken Fisher 11,081,856 sh (+476.85%)
PRIMECAP Management 37,900,350 sh (+10.46%)
Pioneer Investments 1,199,570 sh (+1.16%)
Murray Stahl 28,537 sh (+0.83%)
John Hussman 2,000 sh (unchged)
Dodge & Cox 56,669,449 sh (-0.42%)
Charles Brandes 231,588 sh (-2.19%)
NWQ Managers 495,175 sh (-30.35%)
Sarah Ketterer 414,856 sh (-43.56%)
» More
Q3 2017

AZN Guru Trades in Q3 2017

Jeremy Grantham 18,800 sh (New)
Steven Cohen 1,224,939 sh (+103.10%)
Sarah Ketterer 777,457 sh (+87.40%)
NWQ Managers 577,875 sh (+16.70%)
PRIMECAP Management 43,435,530 sh (+14.60%)
Murray Stahl 31,245 sh (+9.49%)
Ken Fisher 11,601,573 sh (+4.69%)
Charles Brandes 241,197 sh (+4.15%)
John Hussman 2,000 sh (unchged)
David Dreman 180 sh (unchged)
Jim Simons Sold Out
Pioneer Investments 1,194,759 sh (-0.40%)
Dodge & Cox 56,200,178 sh (-0.83%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-09-30 Reduce -0.83%0.01%$28.88 - $34.16 $ 33.466%56,200,178
Ken Fisher 2017-09-30 Add 4.69%0.03%$28.88 - $34.16 $ 33.466%11,601,573
NWQ Managers 2017-09-30 Add 16.70%0.04%$28.88 - $34.16 $ 33.466%577,875
Charles Brandes 2017-09-30 Add 4.15%0.01%$28.88 - $34.16 $ 33.466%241,197
Dodge & Cox 2017-06-30 Reduce -0.42%0.01%$29.76 - $35.36 $ 33.463%56,669,449
Ken Fisher 2017-06-30 Add 476.85%0.5%$29.76 - $35.36 $ 33.463%11,081,856
NWQ Managers 2017-06-30 Reduce -30.35%0.09%$29.76 - $35.36 $ 33.463%495,175
Charles Brandes 2017-06-30 Reduce -2.19%$29.76 - $35.36 $ 33.463%231,588
David Dreman 2017-06-30 New Buy$29.76 - $35.36 $ 33.463%180
Dodge & Cox 2017-03-31 Add 14.70%0.19%$26.72 - $31.8 $ 33.4615%56,906,499
Ken Fisher 2017-03-31 Reduce -1.53%$26.72 - $31.8 $ 33.4615%1,921,092
NWQ Managers 2017-03-31 Reduce -24.78%0.09%$26.72 - $31.8 $ 33.4615%710,935
Charles Brandes 2017-03-31 New Buy0.11%$26.72 - $31.8 $ 33.4615%236,779
David Dreman 2017-03-31 Sold Out $26.72 - $31.8 $ 33.4615%0
Dodge & Cox 2016-12-31 Add 17.60%0.18%$25.81 - $33 $ 33.4618%49,613,588
Ken Fisher 2016-12-31 Reduce -1.34%$25.81 - $33 $ 33.4618%1,950,999
NWQ Managers 2016-12-31 Add 12.55%0.04%$25.81 - $33 $ 33.4618%945,170
David Dreman 2016-12-31 Reduce -86.37%0.03%$25.81 - $33 $ 33.4618%180
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:LSE:GSK, NYSE:LLY, NYSE:BMY, XTER:BAYN, XPAR:SAN, TSE:4503, TSE:4519, TSE:4578, NYSE:ABBV, TSE:4568, TSE:4528, HKSE:01093, TSE:4151, MIL:REC, NYSE:MRK, BOM:500087, BOM:500302, TSE:4536, SHSE:600436, SHSE:600867 » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, AZN.Switzerland, AZN.UK, AZNCF.USA,
Headquarter Location:UK
AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience. The majority of sales come from international markets with the United States representing slightly less than 30% of its sales.

Guru Investment Theses on AstraZeneca PLC

Dodge & Cox Funds Comments on AstraZeneca - Aug 01, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatments for cancer, respiratory illnesses, cardiovascular problems, and infectious diseases. In the second half of 2016, the share price was under pressure due to concerns about recent and upcoming patent expirations for several of its major drugs. Despite this headwind, we added to the Fund’s holding in early 2017 after reaffirming our investment thesis.



The company’s long -term growth outlook is favorable given its robust new drug pipeline, particularly in oncology (cancer treatment). AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease-fighting capabilities of the body’s immune system to attack cancerous tumors. We have conducted extensive due diligence, which included industry conferences and management meetings, and we continue to believe the immuno-oncology (IO) field holds great promise. Since the IO market is in its very early stages, sponsors and the scientific community are



investing heavily into understanding which tumors can be targeted with IO and which patients will be most responsive to IO treatments (i.e., biomarkers). We think the field will evolve rapidly over the next five to ten years as physicians develop a better understanding of how these drugs work, creating a massive revenue and profit opportunity. With a 4.3% dividend yield, the current valuation is reasonable at 17 times forward earnings and does not appear to reflect potential success from the immunotherapy drug pipeline. AstraZeneca shares represented 1.9% of the Fund on June 30.



From Dodge & Cox Stock Funds second quarter 2017 shareholder letter.



Check out Dodge & Cox latest stock trades

Dodge & Cox Comments on AstraZeneca - Feb 06, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline.





From Dodge & Cox's Global Stock Fund 4th quarter 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about AstraZeneca PLC

FASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic Asthma
Despite Profit Beat, Merck Shares Fall Due to Impact of NotPetya Attack Pharmaceutical company raises guidance for the year
Drugmaker Merck & Co. Inc. (NYSE:MRK) reported its third-quarter results before the opening bell on Oct. 26. Read more...
Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma
Dodge & Cox Funds Comments on AstraZeneca Guru stock highlight
AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatments for cancer, respiratory illnesses, cardiovascular problems, and infectious diseases. In the second half of 2016, the share price was under pressure due to concerns about recent and upcoming patent expirations for several of its major drugs. Despite this headwind, we added to the Fund’s holding in early 2017 after reaffirming our investment thesis. Read more...
Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma How the company's latest development makes it a potential takeover target
If you would have mentioned the name Emmaus Life Sciences to an investor, even one familiar with the biotechnology space, a couple of months ago, chances are the said investor would not have had any idea who you were talking about. In fact, the same probably applies today. Read more...
Charles Brandes Invests in Health Care in 1st Quarter Guru buys AstraZeneca, CVS, Gilead Sciences, others
Charles Brandes (Trades, Portfolio)’ Brandes Investment Partners gained 49 new holdings during the quarter. Among the purchases were several health care stocks. His three largest new health care holdings are AstraZeneca PLC (NYSE:AZN), CVS Health Corp. (NYSE:CVS) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
Causeway International Value Buys AstraZeneca, Gildan Fund invests in biopharmaceuticals, apparel in 4th quarter
Sarah Ketterer (Trades, Portfolio)’s Causeway International Value (Trades, Portfolio) added two holdings to its portfolio during the fourth quarter. They are AstraZeneca PLC (LSE:AZN) and Gildan Activewear Inc. (TSX:GIL). Read more...
Dodge & Cox Comments on AstraZeneca Guru stock highlight
AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline. Read more...

Ratios

vs
industry
vs
history
PE Ratio 22.61
AZN's PE Ratio is ranked higher than
64% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. AZN: 22.61 )
Ranked among companies with meaningful PE Ratio only.
AZN' s PE Ratio Range Over the Past 10 Years
Min: 6.03  Med: 12.35 Max: 99.64
Current: 22.61
6.03
99.64
Forward PE Ratio 17.51
AZN's Forward PE Ratio is ranked higher than
54% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.53 vs. AZN: 17.51 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.61
AZN's PE Ratio without NRI is ranked higher than
65% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. AZN: 22.61 )
Ranked among companies with meaningful PE Ratio without NRI only.
AZN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.03  Med: 12.35 Max: 99.64
Current: 22.61
6.03
99.64
Price-to-Owner-Earnings 14.75
AZN's Price-to-Owner-Earnings is ranked higher than
75% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.43 vs. AZN: 14.75 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AZN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.37  Med: 11.6 Max: 45.35
Current: 14.75
5.37
45.35
PB Ratio 6.12
AZN's PB Ratio is ranked lower than
79% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. AZN: 6.12 )
Ranked among companies with meaningful PB Ratio only.
AZN' s PB Ratio Range Over the Past 10 Years
Min: 2.3  Med: 3.82 Max: 6.93
Current: 6.12
2.3
6.93
PS Ratio 3.61
AZN's PS Ratio is ranked lower than
58% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. AZN: 3.61 )
Ranked among companies with meaningful PS Ratio only.
AZN' s PS Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.4 Max: 4.03
Current: 3.61
1.61
4.03
Price-to-Free-Cash-Flow 29.03
AZN's Price-to-Free-Cash-Flow is ranked lower than
80% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. AZN: 29.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AZN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.18  Med: 14.21 Max: 179.65
Current: 29.03
6.18
179.65
Price-to-Operating-Cash-Flow 17.91
AZN's Price-to-Operating-Cash-Flow is ranked lower than
68% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. AZN: 17.91 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AZN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.35  Med: 8.62 Max: 33.31
Current: 17.91
5.35
33.31
EV-to-EBIT 19.26
AZN's EV-to-EBIT is ranked lower than
53% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. AZN: 19.26 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.2  Med: 8.5 Max: 61
Current: 19.26
4.2
61
EV-to-EBITDA 12.70
AZN's EV-to-EBITDA is ranked higher than
62% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. AZN: 12.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.6  Med: 6.8 Max: 20.6
Current: 12.7
3.6
20.6
EV-to-Revenue 4.22
AZN's EV-to-Revenue is ranked lower than
60% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. AZN: 4.22 )
Ranked among companies with meaningful EV-to-Revenue only.
AZN' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 2.5 Max: 4.7
Current: 4.22
1.6
4.7
Shiller PE Ratio 18.90
AZN's Shiller PE Ratio is ranked higher than
80% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. AZN: 18.90 )
Ranked among companies with meaningful Shiller PE Ratio only.
AZN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10  Med: 13.79 Max: 20.61
Current: 18.9
10
20.61
Current Ratio 0.94
AZN's Current Ratio is ranked lower than
92% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. AZN: 0.94 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.46 Max: 2.03
Current: 0.94
0.64
2.03
Quick Ratio 0.72
AZN's Quick Ratio is ranked lower than
89% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. AZN: 0.72 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.23 Max: 2.03
Current: 0.72
0.54
2.03
Days Inventory 229.96
AZN's Days Inventory is ranked lower than
88% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. AZN: 229.96 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 122.03 Max: 182.28
Current: 229.96
88.45
182.28
Days Sales Outstanding 82.44
AZN's Days Sales Outstanding is ranked lower than
60% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. AZN: 82.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.99  Med: 71.38 Max: 95.12
Current: 82.44
40.99
95.12

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.18
AZN's Dividend Yield % is ranked higher than
92% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. AZN: 4.18 )
Ranked among companies with meaningful Dividend Yield % only.
AZN' s Dividend Yield % Range Over the Past 10 Years
Min: 2.67  Med: 4.6 Max: 6.88
Current: 4.18
2.67
6.88
Dividend Payout Ratio 1.00
AZN's Dividend Payout Ratio is ranked lower than
88% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 1.00 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AZN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.37  Med: 0.53 Max: 2.89
Current: 1
0.37
2.89
3-Year Dividend Growth Rate 9.10
AZN's 3-Year Dividend Growth Rate is ranked higher than
56% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. AZN: 9.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AZN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -4.5  Med: 9.5 Max: 41
Current: 9.1
-4.5
41
Forward Dividend Yield % 2.69
AZN's Forward Dividend Yield % is ranked higher than
91% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. AZN: 2.69 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.10
AZN's 5-Year Yield-on-Cost % is ranked higher than
90% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. AZN: 5.10 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AZN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.25  Med: 5.6 Max: 8.37
Current: 5.1
3.25
8.37
3-Year Average Share Buyback Ratio -0.20
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. AZN: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.3  Med: 1.1 Max: 4.9
Current: -0.2
-23.3
4.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.29
AZN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
50% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. AZN: 2.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AZN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.48  Med: 1.44 Max: 8.67
Current: 2.29
0.48
8.67
Price-to-Median-PS-Value 1.51
AZN's Price-to-Median-PS-Value is ranked lower than
78% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. AZN: 1.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AZN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.23 Max: 2.47
Current: 1.51
0.57
2.47
Earnings Yield (Greenblatt) % 5.19
AZN's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. AZN: 5.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AZN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 11.8 Max: 23.6
Current: 5.19
1.6
23.6
Forward Rate of Return (Yacktman) % -3.62
AZN's Forward Rate of Return (Yacktman) % is ranked lower than
83% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. AZN: -3.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AZN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17.7  Med: 18.5 Max: 27.6
Current: -3.62
-17.7
27.6

More Statistics

Revenue (TTM) (Mil) $22,273.00
EPS (TTM) $ 1.40
Beta0.65
Short Percentage of Float0.00%
52-Week Range $25.55 - 35.60
Shares Outstanding (Mil)2,531.90 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 22,049 22,408 25,243
EPS ($) 1.77 1.77 2.40
EPS without NRI ($) 1.77 1.77 2.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.83%
Dividends per Share ($) 1.41 1.44 1.47

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}